Kodiak Sciences Target of Unusually High Options Trading (NASDAQ:KOD)

Kodiak Sciences Inc. (NASDAQ:KOD) saw some unusual options trading activity on Thursday. Investors purchased 3,472 put options on the stock. This is an increase of approximately 1,256% compared to the typical volume of 256 put options.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KOD. Baker BROS. Advisors LP raised its stake in shares of Kodiak Sciences by 15.1% in the 4th quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock valued at $556,940,000 after acquiring an additional 2,608,696 shares during the period. Braidwell LP purchased a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $57,955,000. RTW Investments LP purchased a new position in shares of Kodiak Sciences during the 4th quarter worth approximately $41,603,000. Janus Henderson Group PLC acquired a new stake in Kodiak Sciences in the 4th quarter valued at approximately $27,950,000. Finally, Goldman Sachs Group Inc. increased its holdings in Kodiak Sciences by 298.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,303,030 shares of the company’s stock valued at $36,433,000 after purchasing an additional 976,254 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Price Performance

KOD traded down $2.76 during trading hours on Friday, reaching $37.00. The company’s stock had a trading volume of 5,253,123 shares, compared to its average volume of 1,273,219. The stock has a market cap of $1.96 billion, a PE ratio of -8.98 and a beta of 2.61. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $45.60. The business’s 50-day moving average is $25.14 and its 200-day moving average is $21.81.

Analysts Set New Price Targets

A number of analysts have commented on the stock. UBS Group increased their price objective on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright restated a “buy” rating and set a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.43.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.